Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Procter & Gamble Company v. Teva Pharmaceuticals USA Inc. (D. Del. 2008)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Small Molecule Drugs cited in Procter & Gamble Company v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Procter & Gamble Company v. Teva Pharmaceuticals USA Inc. (D. Del. 2008)

Date Filed Document No. Description Snippet Link To Document
2008-02-01 1 Complaint phosphate membolism.. BACKGROUND ART UUS. Pat. No, 3,683,080, issued Aug` B, 1972, to Francis, discloses compositions…United States Patent nn Benedict et al. [11} Patent Number: 5,583,122 [45] Bate of Patent: Dec. 10, 1996…Action This is an action for patent infringement arising under the patent laws of the United States, Title…the owner by assignment of U,S~ Patent No. 5,583,122 (“the ‘ 122 Patent”), entitled “Piiarrnaceutical Cornpositions…copy of the ‘122 Patent is attached hereto as Exhibit A. The ciaixns of the ‘122 Patent are valid and enforceable External link to document
2008-03-20 12 Response to Motion 1. Claims 4, 16, and 23 of U.S. Patent No. 5,583,122 (“the ’122 patent”) are not invalid; 2. Pursuant…the Patent Office to extend a patent term in certain cases in which the marketing of the patented product… tacked on to the patent term, it is not a patent right. The existence of the patent simply provides a…P&G Cannot Extend the ’122 Patent The only “extension” of a patent term pertinent here is governed…the patent was more than 14 years at the time the FDA first approved risedronate, the ’122 patent is ineligible External link to document
2008-03-27 13 Reply to Response to Motion Claims 4, 36, and 23 oli"llSn Patent No, 5,583,122 (“the ’122 patent”); AND tT IS FURTHER ORDERED AND…ADJUDGED that claims 4, 16, and 23 o'l the ‘ 122 patent are valid and enl"orceable; AND iT IS FURTI…the date of"expiration of"the "122 patent, including any extensions and regulatory exclusivities…United States any products that infringe the ‘122 patent, incitiding the 75 mg risedronate sodium tabiets…Application Not 79- 2}5, until the expiration of the ‘122 patent (Decernber 10, 201.3), inchiding any extensions External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.